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BACKGROUND: We have recently reported an inverse relationship between colon cancer progression and tumour proliferative activity.
Here, we extend our findings by evaluating the proliferative activity of liver metastatic lesions and primary colorectal cancers (CRC)
that differ in their metastatic potential.
METHODS: Using an earlier established multi-gene proliferation signature (GPS), proliferative levels were analysed in 73 primary CRCs
and 27 liver metastases.
RESULTS: Compared with primary CRCs, we observed a significantly lower expression of the GPS in liver metastases and confirmed
their lower proliferative levels by quantitative RT–PCR and Ki-67 immunostaining. No difference could be detected in apoptotic
indices as assessed by M30 immunostaining, indicating that the net growth rate is lower in metastases relative to primary tumours.
Notably, relapsed primaries or those with established metastases had significantly lower proliferative activity than CRCs that were
non-metastatic and did not relapse.
CONCLUSION: Our results suggest that slow proliferation is a biological characteristic of both liver metastases and those primary
tumours with the ability to metastasise. The delineation of the mechanisms underlying the inverse association between proliferation
and CRC aggressiveness may be important for the development of new therapeutic strategies.
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Metastasis is the major cause of cancer death. The underlying
process consists of a series of interrelated biological steps that
eventually lead to the formation of metastatic lesions. This highly
selective process favours the survival and proliferation of a sub-
population of cancer cells with the ability to complete all steps. In
addition to these intrinsic features of metastatic cells, their
interaction with the host organ is another potential determinant
of successful metastasis formation (Steeg, 2006). However, our
knowledge of the mechanisms driving the spread of primary
tumours is limited.
Colorectal cancer (CRC) is one of the most common causes of
cancer-related mortality in the Western world and metastasis to the
liver is responsible for a large proportion of the deaths from CRC.
Approximately 50% of CRC patients develop liver metastases
during the course of their disease (Bird et al, 2006). Although
surgery and adjuvant therapy can effectively control CRCs at the
primary site, 80–90% of metastatic lesions are not resectable
(Adam and Vinet, 2004). Even with access to modern chemotherapy
drugs, non-operable patients have a median survival rate of less
than 2 years (Wolpin and Mayer, 2008). A deeper understanding of
the biology of metastasis may improve the ability to identify
patients at high risk of developing metastases and lead to the
discovery of better treatments for established metastatic disease.
A fundamental feature of cancer cells is their altered prolif-
erative rate, which is often used as a basis for current
chemotherapies. We, however, have recently reported an inverse
relationship between the proliferative activity of primary colon
cancers and their malignant potential by utilising a multi-gene
proliferation signature (GPS) (Anjomshoaa et al, 2008). The GPS
provides an objective and robust assay for the assessment of
proliferation, as its expression is increased relative to quiescent
cells in both (i) proliferating CRC cells in vitro and (ii) the
proliferative region of colonic crypts in vivo. The GPS was tested
on breast cancer, where it correctly identified the well-established
association between increased proliferation and worse outcome.
However, when the GPS was used to analyse biopsy material from
two independent cohorts of colon cancer patients, lower cellular
proliferation was found to be associated with advanced disease
stages and a shorter disease-free survival. Of note, these
associations were independent of adjuvant chemotherapy received
by some patients.
Here, we present evidence corroborating the association
between more aggressive biological behaviour and low prolifera-
tion in CRC by analysing CRC liver metastases and a series of
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sprimary tumours differing in metastatic potential. We found
that both metastasising primaries and liver metastases are
characterised by a reduced proliferative activity relative to non-
metastatic CRCs.
MATERIALS AND METHODS
Patients and tumour samples
Tumour specimens were obtained from 73 patients undergoing
surgery for primary CRC at Dunedin Public Hospital and 27 patients
undergoing resection of CRC liver metastases at Auckland City
Hospital, New Zealand. Fresh frozen specimens were taken from each
tumour and stored at  801C. Formalin-fixed paraffin-embedded
tissue blocks were also available. Ethical Committee approval was
obtained and all participants gave signed informed consent.
The primary tumours and liver metastases were not paired. Of
the 27 patients operated on for liver metastases, 10 had
synchronous and 17 had metachronous disease. Of the 73 primary
tumours, 40 were situated in the colon and 33 were rectosigmoid
or rectal. Ten had stage I, 27 stage II, 28 stage III and 8 stage IV
disease. Patients were followed up for a minimum of 5 years. Of the
65 patients with primary CRC who underwent potentially curative
resection (stage I–III patients), 24 developed disease relapse, 21 of
which included systemic spread. Three isolated local relapses were
not included in the analyses.
Array preparation and gene expression analysis
Gene expression profiling of all tumours was performed using
arrays spotted with an MWG 30K Oligo Set (MWG Biotech,
Winston-Salem, NC, USA) as described previously (Anjomshoaa
et al, 2008). Briefly, Cy dyes were incorporated into cDNAs
synthesised from 10mg tumour sample or reference RNA using the
indirect amino-allyl cDNA labelling method. A pooled RNA sample
derived from a mixture of 12 cell lines was used as a reference for
all hybridisations. The mixture of dye-labelled cDNAs was then
purified and co-hybridised to a microarray. After scanning with a
GenePix 4000B microarray scanner (Molecular devices, Sunnyvale,
CA, USA), the foreground intensities from each channel were log2-
transformed and normalised using the SNOMAD software
(Colantuoni et al, 2002). Normalised values were collated and
filtered using BRB-Array Tools version 3.6.0-b_3 (http://linus.
nci.nih.gov/BRB-ArrayTools.html). Genes of low signal intensity,
or for which more than 20% of measurements across tumour
samples were missing, were excluded from further analysis.
Quantitative real-time–PCR
The expression of seven randomly selected genes from the GPS
(MAD2L1, POLE2, CDC2, MCM6, MCM3, PBK and GMNN) and
two well-known proliferative genes (PCNA and Ki-67) was
validated by quantitative real-time–PCR (qRT–PCR) on an ABI
Prism 7900HT system, Applied Biosystems, Foster City, NC, USA.
Relative fold changes were calculated using the 2
 DDCT method
(Livak and Schmittgen, 2001). Topoisomerase 3A (TOP3A) was
used as the internal control because it had the least expression
variation across samples compared with other potential house-
keeping genes (i.e. ACTB, DSP, BAZ2A). Reference RNA (the same
reference as for microarrays) was used as a calibrator to enable
comparison between different experiments.
Immunohistochemistry
Immunohistochemical assessment of proliferation and apoptosis
was performed in all tumours. Antigens were retrieved on 4mm
sections in boiling citrate buffer (pH 6). Primary antibodies (MIB-
1/Ki-67 and M30 Cytodeath; dilution 1:50; Dako Glostrup,
Denmark) were detected using the EnVision system (Dako) and
the DAB substrate kit (Vector Laboratories, Burlingame, CA, USA).
For each tumour sample, cells within five high-power fields were
counted by two observers in a blinded manner. The proliferative
and apoptotic indices were presented as percentage of positively
stained cells.
Statistical analysis
All microarray analyses were performed using BRB-Array Tools
software. Testing for significant differences in the GPS expression
or immunohistochemical indices between groups of tumours was
carried out with SPSS 15.0.0 (SPSS Inc., Chicago, IL, USA). A
multiple comparisons correction (Bonferroni) was applied to the
P-values derived from testing for differences in microarray-based
gene expression. Additional details relating to the statistical
methods and their specified parameters are described in the
corresponding results sections.
RESULTS
Lower GPS expression in liver metastases compared with
primary CRCs
To investigate whether liver metastases and primary CRCs differ
in their proliferative activity, the expression of genes constituting
our GPS was compared between the two tumour groups.
Expression values for the GPS genes were obtained from the
array-generated expression profiles. Expression data were available
for 33 out of the 36 GPS genes. CDCA5, KIF4A and GINS2 were
filtered out due to the poor quality of spots. We first examined
whether GPS expression differs between tumours of rectal
and colonic origin. Because the GPS levels were similar in the
rectal and colonic groups (adjusted P40.4, two-tailed t-test
based on 1000 permutations), rectal and colon tumours were
considered as one group in all subsequent analyses. Intriguingly,
30 out of the 33 GPS genes had significantly lower expression in
liver metastases compared with primary CRCs (adjusted Po0.01;
two-tailed t-test) (Supplementary Table 1). Only three genes
(CDC20, NOLA2 and SSX2IP) had similar expression levels. These
results suggest that liver metastases are less proliferative than
primary CRCs.
Lower expression by qRT–PCR of GPS genes in liver
metastases compared with primary CRCs
To validate the microarray data, seven genes from the GPS
(MAD2L1, POLE2, CDC2, MCM6, MCM3, PBK and GMNN) and
two established proliferation-related genes (PCNA and Ki-67) were
assessed by qRT–PCR. As shown in Figure 1, all examined
genes displayed significantly lower expression in liver metastases
relative to primary CRCs (Po0.005; Mann–Whitney U-test).
Strong (correlation coefficients 0.74–0.86) and highly signifi-
cant (Po0.001; Spearman’s correlation test) correlation was
observed between the microarray- and qRT–PCR-generated
expression data.
Lower Ki-67 labelling index in liver metastases compared
with primary CRCs
To determine whether liver metastases and primary CRCs differ in
Ki-67 nuclear expression, the Ki-67 labelling index (LI) was
compared between the two groups (Figure 2A and B). Median
(range) Ki-67 LI was 81.8% (25.1–96.4%) in primary CRCs, and
36.2% (12.1–65.5%) in liver metastases (Po0.001; Mann–Whitney
U-test; Figure 2C).
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primary CRCs
To determine whether liver metastases and primary CRCs differ in
apoptotic rates, the M30 apoptotic index (AI) was assessed in the
two groups (Figure 2D and E). Median (range) M30 AI was 4.28%
(0.83–17.95%) in primary CRCs and 3.91% (1.45–11.2%) in liver
metastases. No significant difference in the M30 AI was detected
between primary CRCs and liver metastases (P¼0.68; Mann–
Whitney U-test; Figure 2F). The observation of lower proliferative
index of liver metastases relative to primaries, together with a
similar AI, indicates that the net growth rate is lower in liver
metastases than in primary CRCs.
Slow proliferation is a biological feature of CRC metastasis
Because metastatic lesions are the result of a process that is
initiated at the primary tumour site, they should share biological
features with primary tumours that have a high metastatic
potential. We therefore hypothesised that primary CRCs with a
high metastatic potential have slower proliferative rates than CRCs
with a low metastatic potential. To test this hypothesis, GPS genes
were first averaged to assign each tumour a mean GPS score. GPS
scores were then compared between groups of tumours classified
according to the tumour stage or relapse status. P-values were
calculated using the Exact test option in SPSS, which provides
more accurate estimates of significance for non-parametric tests
when dealing with small sample sizes. The Mann–Whitney U-test
was used for comparison of two groups and Kruskal–Wallis test
for comparison of more than two groups. The results are
summarised below:
(A) To determine whether tumour proliferation is related to the
presence of metastasis at the time of surgery, GPS scores were
compared between stage I–II and stage III–IV primary
tumours. Stage I and II CRCs were grouped as they were
confined to the intestinal wall and no difference in prolifera-
tion was detected between non-relapsed stage II and I tumours
(P¼0.77). Stage III and IV CRCs were grouped because these
two stages of disease did not differ in proliferation (P¼0.92).
Stage III–IV tumours had significantly lower GPS scores than
stage I–II tumours (P¼0.022; Figure 3A). This analysis
suggests that CRCs with established metastasis to the lymph
nodes or distant organs have lower proliferative activity than
CRCs that were non-metastatic at the time of surgery.
(B) To determine whether slow proliferation in stage I–II tumours
was associated with disease relapse, GPS scores were
compared between the tumours of patients who remained
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Figure 1 Quantitative RT–PCR confirmed the lower expression of nine cell-cycle-related genes in liver metastases compared with primary CRCs. The
Y axis represents the fold changes calculated as the ratio of tumour to reference gene expression, normalised to a control gene. The box range (interquarter
range) contains the middle 50% of the data. The median value is shown as a horizontal line across the box. The extreme values (within 1.5 times the
interquartile range from the upper or lower hinges) are the ends of the whiskers. Points at a greater distance than 1.5 and 3 times of the interquartile range
are outliers and presented as circles and asterisks, respectively. All differences were significant at the a-level of 0.005 using the Mann–Whitney U-test.
Analysis was performed using SPSS software.
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srelapse-free and those who relapsed. All stage I tumours remained
relapse-free, while 7 out of 27 stage II tumours experienced
relapse during a 5-year follow-up. The GPS scores were found to
be significantly lower in the relapsed compared with the non-
relapsed group (P¼0.014; Figure 3B). When analysis was limited
to stage II tumours, the association between tumour proliferation
and relapse remained significant (P¼0.035).
(C) To determine whether proliferation is associated with the
likelihood of relapse in tumours with lymph node metastasis
at the time of surgery, only stage III CRCs were analysed. No
difference in the GPS scores was detected between 11 relapse-
free tumours and 14 tumours that relapsed after surgery
(P¼0.44; Figure 3C). Three tumours had local relapse and
were not included in the analysis. Stage IV tumours were not
analysed as all had residual disease from the time of surgery.
These results suggest that low proliferation is not associated
with the likelihood of relapse but rather with the ability to
disseminate beyond the primary site.
(D) To determine whether slow proliferation is a common feature
of primary tumours with metastasis at the time of surgery and
metastasis during follow-up, the GPS scores of stage III–IV
and stage II CRCs that relapsed during follow-up was
compared. Interestingly, no difference in the GPS scores was
detected (P¼0.78; Figure 3D), indicating that slow prolifera-
tion is part of a metastatic signature common to both. These
results confirm that slow proliferation is associated with the
ability to metastasise as assessed under (C).
(E) To further confirm the association between slow proliferation
and metastatic potential in primary tumours, relapse-free
stage I–II tumours and stage III–IV tumours were analysed.
As expected, GPS scores were significantly lower in stage
III–IV tumours compared with the other group (P¼0.013;
Figure 3E).
(F) To determine whether CRC proliferative activity inversely
correlates with increasing metastatic potential, we compared
GPS scores between three groups of tumours. Group 1 (non-
metastatic CRCs) included stage I–II tumours from patients
who remained relapse-free. Group 2 (metastatic CRCs)
included stage III–IV and stage II tumours from patients
who developed relapse. Group 3 included the liver metastases.
GPS scores were significantly different between the three
groups (P¼0.001; Figure 3F). Proliferative activity increased
from liver metastases to metastatic primaries and was highest
in non-metastatic primaries, confirming that slow prolifera-
tion is related to the ability of CRCs to metastasise.
Gene set comparison analysis confirms the significant
differences in the GPS between tumour groups differing in
their metastatic potential
To confirm the significant differences in proliferative activity of
the tumour groups defined above (A–F), we used gene set
comparison analysis as an alternative approach. When comparing
different tumour groups, the GPS was considered to have a higher
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Figure 2 Nuclear staining of Ki-67 protein in a primary CRC (A) and a liver metastasis (B). Cytoplasmic staining of M30 apoptotic protein in a primary
CRC (D) and a liver metastasis (E). The Ki-67 LI was significantly lower in liver metastases compared with primary CRCs (C). No significant difference was
observed in M30 AI between liver metastases and primary CRCs (F). P-values were calculated using the Mann–Whitney U-test.
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sthan expected number of differentially expressed genes if the
Kolmogorov–Smirnov (KS) re-sampling P-value was less than
0.005 (default value). The distribution of KS statistics was obtained
following 100000 random re-sampling events. Gene set compar-
ison analysis confirmed that the GPS contained a higher than
random proportion of DE genes among groups as was observed
with the non-parametric tests (data not shown).
Altogether, the comparison of GPS levels in the various CRC
groups strongly suggests that slow proliferation is a biological
feature of CRCs that have the potential to metastasise.
DISCUSSION
Dysregulated cellular proliferation is a defining characteristic of
cancer. It is therefore not surprising that cell proliferation has
received considerable attention in the field of cancer biology and
has been extensively studied as a means to predict the behaviour of
tumours. The general perception says that a selective growth
advantage is fundamental to the development and progression of
cancers. Many studies support this concept by demonstrating that
more aggressive tumours have a higher proliferative capacity
(Rosenwald et al, 2003; Krasnoselsky et al, 2004; Dai et al, 2005).
However, we have recently reported that the opposite is true in
colon cancer (Anjomshoaa et al, 2008).
In the present study, the significantly lower proliferative activity
of liver metastases relative to primary CRCs provides additional
evidence for a correlation between slow proliferation and high
aggressiveness of CRC. Our conclusion is based on the differential
expression of multiple proliferation-associated genes (the GPS)
between liver metastases and primary CRCs, which was confirmed
by single-gene quantitative RT–PCR assays. Furthermore, Ki-67
immunostaining confirmed the low levels of proliferation in CRC
metastases and demonstrated that the difference in the prolif-
erative activity between liver metastases and primary CRCs was
large enough to be detected by a subjective single-protein assay.
Finally, the combination of a lower proliferative activity with a
similar AI in metastases relative to primaries is consistent with the
clinical observation that liver metastases are sometimes slow
growing. Other groups using immunohistochemical methods have
come to similar conclusions (Thomas et al, 1998; Agui et al, 2002;
Kitabatake et al, 2002; Seong et al, 2004).
An important observation in our study is that low relative
proliferation appears to be a biological feature of CRCs with a high
metastatic potential. This viewpoint is strongly supported by the
GPS-based analysis of primary CRCs, where groups of highly
malignant tumours (high stage and relapse) displayed low
proliferative activity relative to less malignant tumours (low stage
and low risk of relapse). All observed associations between
metastatic capacity of primary CRCs and their proliferative
activity also hold up in the cohort of 108 tumours analysed in
our earlier study (Anjomshoaa et al, 2008). The low proliferation of
metastatic CRCs was intermediate between that of non-metastatic
CRCs and liver metastases, further strengthening this view. This is
consistent with the expression profiling studies that have
demonstrated a substantial signature overlap between metastases
and their original primaries, but a lack thereof between metastatic and
non-metastatic primaries (Koehler et al, 2004; D’Arrigo et al, 2005).
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Figure 3 Box plots summarising the distribution and variability of GPS scores in defined classes of CRCs. GPS expressions for 33 genes (log2 target/
reference) were first averaged for each sample, and then transformed into fold changes as GPS scores. The exact levels of significance were calculated using
the Exact method implemented in Mann–Whitney U-test (for comparison of two groups) and Kruskal–Wallis test (for comparison of more than two
groups). Resulting P-values are indicated in the right upper part of each panel. Numbers in the upper left of plots refer to the corresponding paragraphs in
the manuscript. The interpretation of box plots has been described in the legend of Figure 1.
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sWe therefore propose that reduced proliferative activity is part of a
biological signature that renders CRCs aggressive.
There are some strengths and weaknesses in this study. Strengths
include the multi-gene method of assessing proliferation, which has
been validated earlier (Anjomshoaa et al, 2008) and was further
validated in this study by RT–PCR and an established immuno-
histochemical method for the measurement of proliferation. Another
strength is the long and complete follow-up in our cohort of patients
with primary CRC, which minimises the risk of mis-classification
when separating the groups according to relapse. A weakness of the
study is that the 27 patients with liver metastases all underwent liver
resection, yet the majority of patients with liver metastases from CRC
are not resectable. This cohort may thus not be representative of the
broader group with liver metastases. This limitation was imposed
because it is difficult to obtain fresh tumour samples from patients
with unresectable liver metastases. Nonetheless, it seems unlikely
that the biological behaviour of resectable liver metastases will
significantly differ from that of non-resectable ones with respect to
the relative proliferation levels. Furthermore, the fact that the
primaries and metastatic lesions were not matched limits the
assessment of the relative proliferation differences. In addition,
although we could not detect any difference in proliferation between
tumours with metastasis to the lymph nodes and those with distant
organ metastasis, this result remains speculative because of the small
numbers of stage IV tumours.
Given that metastasis is a highly selective process and distant
metastases arise from a small sub-population of aggressive cells
within the heterogeneous primary lesion, it is conceivable that the
biological features of the original cells will manifest themselves in
the metastatic lesion. If the cells of origin are slow proliferating
and resistant to apoptosis, the cells at the metastatic sites are likely
to be as well. Consistent with this scenario are the intermediate
proliferative levels of metastatic primaries (a sub-population of
slow-growing cells within a heterogeneous tumour) and the low
levels of variation among the GPS genes in the metastases (where a
single invading cell has produced a clone at a distant site; see also
Figure 1). In this context, the ability to survive in the secondary
organ may dominate the need to proliferate fast. However,
inhibitory growth signals and an inappropriate (non-physiologi-
cal) environment at the host organ site may also contribute to the
slow proliferation of liver metastases (Hara et al, 2000).
There are a number of plausible mechanisms that could underlie
the association between low cellular proliferation and disease
progression in CRC. Although it is intuitively logical that
accelerated cell division allows for more genetic errors to
accumulate and to promote tumour progression, slow proliferation
can be a feature of cancer cells with the ability to spread. For
example, the presence of dissociated, dedifferentiated tumour cells
(budding cells) at the tumour–host interface correlates with an
enhanced malignant potential in CRC (Prall, 2007). It is
noteworthy that budding cells have undergone an epithelial–
mesenchymal transition (EMT) and are growth arrested due to
increased expression of the cell-cycle-dependent kinase inhibitor,
P16 and other unknown mechanisms (Jung et al, 2001).
Furthermore, low cellular proliferation at the invasive margin
has been associated with poor prognosis in CRC (Palmqvist et al,
1999). Therefore, CRCs with a high proportion of dedifferentiated
cells or with an extensive tumour–host interface may be more
slowly proliferating but aggressive.
Tumour cells at the tumour–host interface not only express
EMT-associated genes, but also increase the expression of
stemness-associated genes and therefore are considered to be
migratory cancer stem cells (Brabletz et al, 2005). Cancer stem cells
are relatively quiescent (Boman et al, 2008), raising the possibility
that the metastatic potential of slow-proliferating CRCs may be
due to the presence of a high proportion of cancer stem cells.
Another possible reason for the association between low cellular
proliferation and poor prognosis could be related to chronic and acute
hypoxic regions present in CRCs. It has been shown that hypoxic
conditions may slow down the growth rate of tumours but can
promote the onset of an EMT leading to invasion (Yang et al, 2008).
Aneuploidy, an abnormal chromosome number, may provide an
additional explanation for the association of low proliferation with
high metastatic potential. Aneuploidy would be expected to have
dramatic consequences on basic cellular functions such as
proliferation. In budding yeast, for example, aneuploidy in the
form of extra chromosome gains was found to result in a
proliferative disadvantage (Torres et al, 2007). This same
phenomenon occurs when mammalian cells carry additional
chromosomes. In a recent publication, trisomic mouse embryonic
fibroblasts were shown to proliferate more slowly than the euploid
controls (Williams et al, 2008). Furthermore, a high level of
chromosomal instability inhibits tumour growth, probably owing
to inefficient cell proliferation or apoptotic induction (Weaver
et al, 2007; Garcia-Higuera et al, 2008). All these studies suggest
that aneuploidy hampers cell proliferation in human cells. These
findings along with the established association between aneuploidy
and a bad outcome in CRC (Araujo et al, 2007) suggest that the
aneuploid state of more aggressive CRCs is one likely (but by no
means the only) cause for the low proliferative activity of
metastatic CRC. Possible underlying mechanisms are currently
under investigation in our laboratory.
The extremely poor survival for patients with metastatic disease
highlights the need for improved treatments. This requires the
elucidation of the molecular and cellular mechanisms underlying
CRC metastasis. The intriguing finding of an inverse relationship
between tumour proliferation and metastasis suggests that slow
proliferation is an important biological feature of a metastatic
signature in CRC. This suggests that cytotoxic drugs killing fast-
proliferating cells may not necessarily be the best choice for the
treatment of metastatic disease. Therefore, the delineation of the
mechanisms that underlie this biological feature of CRC may lead
to the development of novel antimetastatic treatment strategies.
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